HIGHLIGHTS
- who: Francesco De Sanctis from the Immunology Section, University Hospital and Department of Medicine, University of Verona, Verona, Italy have published the article: Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy, in the Journal: (JOURNAL)
- what: In this scenario, TAMs and MDSCs represent the ultimate commitment of the tumour-dependent myeloid-cell reprogramming and will be the focus of this review.
- future: Strategies harnessing T_cell functions and myeloid cell reprogramming will synergise in supporting immune system ability to restrict tumour progression in the next future. Antibodies blocking those receptors recently . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.